Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Biotage in connection with its acquisition of ATDBio
Mandate

Vinge has advised Biotage in connection with its acquisition of ATDBio

October 26, 2021 Capital Markets and Public M&A

Vinge has advised Biotage AB (publ), listed on Nasdaq Stockholm, in connection with its acquisition of ATDBio Limited based in Oxford and Southampton, UK, for a total purchase price of approx. 45 MGBP on a debt free and cash free basis (corresponding to approx. 534.4 MSEK) financed through a combination of a share issue of new ordinary Biotage shares, cash at hand and a revolving credit facility. The transaction closed in connection with the entering into of the share purchase agreement.

Vinge’s team consisted of Dain Hård Nevonen, William Kåge and Sara Ottosson Bixo.

 

Related

Vinge has advised Oncopeptides in connection with a directed share issue

 Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

 Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026

Vinge has advised Orexo in connection with its rights issue

 Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026